Enterobacteriaceae (except Proteus, Providencia and Morganella) with reduced susceptibility (,23 mm inhibition zone diameter or MIC .1 mg/L) to any of the carbapenems (ertapenem, imipenem or meropenem) will be tested for the carbapenemase phenotype by the combined disc method (with EDTA or boronic acid).
Sir, The increasing occurrence of infections due to vancomycinresistant enterococci has led to the use of alternative therapeutic agents, including the off-label use of the cyclic lipopeptide daptomycin. We recently treated three patients who developed infections due to daptomycin-non-susceptible Enterococcus faecium (DNSE) after receiving daptomycin. An independent laboratory confirmed daptomycin non-susceptibility and determined the three isolates to be clonally unrelated.
A patient with a metastatic abdominal malignancy received 133 daily doses of daptomycin (6 mg/kg) for a complicated intra-abdominal infection due to methicillin-resistant Staphylococcus aureus. On readmission, blood cultures grew E. faecium susceptible to vancomycin, linezolid and quinupristin/ dalfopristin, but with a daptomycin MIC of 32 mg/L by Etest (AB Biodisk). Confirmation showed a daptomycin MIC of 16 mg/L by broth microdilution and 24 mg/L by Etest (Table 1) . The patient was treated with 15 mg/kg vancomycin intravenously every 12 h for 7 days followed by 600 mg of linezolid orally twice daily for 2 days with complete recovery.
A second patient developed intra-abdominal complications following an orthotopic liver transplant. Vancomycin-resistant E. faecium was isolated from the blood and peritoneal fluid. The daptomycin MIC for both isolates was noted to be 4 mg/L by Etest and 8 mg/kg daptomycin every 48 h was begun.
Intensive support including slow low-efficiency dialysis (SLED) was employed. Three days later, a combined liver -kidney transplant was performed. Repeat culture of the peritoneal fluid grew E. faecium with a daptomycin MIC by Etest of 16 mg/L. Confirmation showed a daptomycin MIC of 8 mg/L by broth microdilution and Etest (Table 1) . Therapy was changed to 600 mg of linezolid intravenously every 12 h, but the patient expired after 6 days of treatment.
A third patient with acute myelogenous leukaemia received seven daily doses of 6 mg/kg daptomycin for abdominal wall cellulitis and a small, superficial abscess (whose drainage was later reported as growing only Pseudomonas aeruginosa). Five months later the patient was admitted with a draining ulcer on the abdomen and treated with 6 mg/kg daptomycin daily. Culture of the drainage grew DNSE (daptomycin MIC .16 mg/L by Etest). Confirmation revealed a daptomycin MIC of 32 mg/L by broth microdilution and 16 mg/L by Etest (Table 1) . Therapy with 600 mg of linezolid orally twice daily for 14 days was completed uneventfully.
Daptomycin non-susceptibility among enterococci has rarely been reported. From the Daptomycin Surveillance Program, 99% of 203 vancomycin-susceptible E. faecium isolates and 99.7% of 640 vancomycin-non-susceptible E. faecium isolates were susceptible to daptomycin (with an MIC ≤4 mg/L), with the highest recorded MIC of 8 mg/L being seen for only four strains. 1 A recent literature review estimated the prevalence of daptomycin non-susceptibility among enterococci at 0.6%; however, several E. faecium isolates were shown by chromosomal testing to be clonally related. 2 In this review, eight patients with DNSE were reported to have received a mean of 32.3 days of daptomycin exposure prior to the isolation of DNSE. Outcomes were documented in only eight cases of DNSE infection, with none achieving a clinical or microbiological cure despite treatment with alternative therapy.
All three of our isolates were E. faecium. Each had chromosomal DNA isolated, digested with the restriction enzyme SmaI and analysed by PFGE. The isolates were found to be clonally unrelated and unique strains that had acquired daptomycin non-susceptibility.
While the mechanism of daptomycin non-susceptibility in enterococci has not been well characterized and no spontaneously resistant mutants of E. faecium have been isolated in vitro, alterations in genes for cardiolipin may be important. 3 -5 Factors that may influence the development of daptomycin non-susceptibility include a lengthy exposure to the drug, 5 deep-seated infections with a heavy bacterial load and limited drug penetration, 2 altered pharmacokinetics in some immunocompromised patients 6 and inadequate dosing schedules due to renal replacement therapy.
7 -9 Each of our patients had at least one of the factors, including factors that could have resulted in the underdosing of daptomycin. Two patients had malignancies and one underwent SLED. Bubalo et al.
6 determined that, in comparison with healthy volunteers, cancer patients had reductions in both the C max and AUC 0 -1 of daptomycin while the volume of distribution and total clearance were increased. Few data are available on daptomycin dosing in extended dialysis, but two studies examining SLED and the clearance of daptomycin suggested that dosing daptomycin every 48 h would result in significant underdosing.
8,9
Until there is a better understanding of the mechanisms of altered daptomycin susceptibility, clinicians should be aware of its uncommon existence. Possible strategies to minimize its development could include limiting lengthy and repeated courses of the drug unless absolutely necessary, using higher doses in complicated infections or neutropenic patients with fever, or increasing the frequency of dosing in patients undergoing slow extended daily dialysis.
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This work was reviewed and approved for submission by Cubist Pharmaceuticals, Inc.; however, the design, findings, conclusions and opinions are those of the authors and not of Cubist Pharmaceuticals, Inc. Sir, With a rapid increase in invasive infections caused by methicillinresistant Staphylococcus aureus (MRSA), there is a demand for antimicrobials with enhanced activity against MRSA. The concentration-dependent, bactericidal lipoglycopeptide telavancin was approved in 2009 for treatment of complicated skin and skin-structure infections due to susceptible organisms. The emergence of glycopeptide resistance and clinical failures of vancomycin therapy in invasive MRSA infections, including osteomyelitis, has led to the unlabelled use of alternatives to vancomycin for treatment of these infections. We report four patients with MRSA osteomyelitis who failed standard vancomycin therapy and were successfully retreated with telavancin and surgical intervention. A patient was admitted with inability to ambulate for 1 day. This was preceded by a 4 day history of progressive leg weakness and a 2 month history of lower back pain. There also was a history of multiple carbuncles of the face, neck and buttocks, but no antimicrobial therapy had been administered for these. No fever was present. White blood cell (WBC) count, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were elevated. Magnetic resonance imaging (MRI) revealed T4 -7 vertebral osteomyelitis as well as T5-6 discitis with an anterior epidural phlegmon and stenosis with spinal cord compression.
T5-6 laminectomy with drainage of the epidural abscess and decompression of the spinal cord was performed. Treatment with cefepime 2 g intravenously (iv) every 8 h and vancomycin 18 mg/kg iv every 12 h was begun. Blood cultures were negative, but MRSA was identified from culture of the abscess 72 h later. Vancomycin MIC was 2 mg/L, linezolid MIC was 2 mg/L and daptomycin MIC was 1 mg/L. Therapy was changed to daptomycin 6 mg/kg iv daily. After the back pain and WBC were noted to have improved, the patient was discharged to a physical rehabilitation centre to complete a planned 8 week course of daptomycin.
Two weeks later, because of progressive leg weakness, fever and re-elevation of WBC, ESR and CRP values, the patient was readmitted. MRI showed recurrent epidural abscess at T5 -6. T4 -6 laminectomy was performed with drainage of the recurrent abscess and cord decompression. Culture of the abscess again grew MRSA (vancomycin MIC 2 mg/L, daptomycin MIC 1 mg/L and telavancin MIC 0.38 mg/L). Treatment was changed to telavancin 10 mg/kg iv daily. While receiving 10 weeks of telavancin therapy, there was resolution of fever and leucocytosis and normalization of ESR and CRP values. Gradual recovery of leg strength and ability to ambulate was noted. There was no evidence of recurrent infection 4 months after completion of telavancin.
A patient with the sudden onset of leg weakness and urinary incontinence was transferred from another hospital after a lengthy hospitalization with MRSA bacteraemia (vancomycin MIC 1 mg/L, linezolid MIC 2 mg/L and daptomycin MIC ≤0.5 mg/L) from cellulitis complicated by sepsis, respiratory failure with pneumonia, renal dysfunction and hepatic encephalopathy. Despite sequential treatment with adequate doses of vancomycin (14 days), linezolid (7 days) and daptomycin (14 days), the MRSA bacteraemia persisted with unchanged MIC values.
Fever was absent. WBC, ESR and CRP values were elevated. Transthoracic echocardiography and transoesophageal echocardiography (TOE) did not reveal valvular vegetations. MRI showed an epidural abscess extending from T6 to L2, L1 vertebral osteomyelitis and a left psoas abscess. Telavancin 10 mg/kg iv daily was begun.
T6-7 decompressive laminectomy was performed and the abscess was evacuated. Cultures of the blood and abscess grew MRSA with unchanged MIC values of vancomycin, linezolid and daptomycin. Telavancin MIC was 0.25 mg/L.
Telavancin was administered for 8 weeks with improvement in leg weakness and normalization of WBC, ESR and CRP values. There was no evidence of recurrence 7 months after completion of telavancin.
A patient presented with a 1 week history of right hip pain after a fall. Fever and leucocytosis were present. There was a remote history of a gunshot wound to the right hip.
CT revealed a 2 cm mass in the left upper lung and a large right hip effusion. MRI was consistent with right hip septic arthritis and osteomyelitis of the right acetabulum, femoral head, femoral neck and lesser trochanter. Blood cultures grew MRSA (vancomycin MIC 1 mg/L, linezolid MIC 1 mg/L and daptomycin MIC ≤0.5 mg/L). Ceftriaxone 2 g iv daily and vancomycin 13 mg/kg iv every 12 h were begun and continued for 5 days.
